Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 12/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28208474 | 0.78 | AR (0.43) | TSHRARUPP1ESR1ESR2 | |
| SCHEMBL27709086 | 0.78 | AR (0.40) | TSHRARALDH1A1UPP1CYP1A2 | |
| SCHEMBL3426156 | 0.78 | AR (0.41) | TSHRAR | |
| SCHEMBL3954053 | 0.78 | TSHR (0.48) | TSHRARALDH1A1 | |
| SCHEMBL1585098 | 0.77 | AR (0.52) | TSHRARALDH1A1UPP1 | |
| Hydrochloric Acid SCHEMBL27670198 | 0.77 | AR (0.39) | TSHRARALDH1A1UPP1CYP1A2 | |
| SCHEMBL29398131 | 0.74 | TSHR (0.44) | TSHRARALDH1A1CYP1A2 | |
| SCHEMBL7056620 | 0.74 | AR (0.47) | TSHRARUPP1TRPA1ESR1 | |
| SCHEMBL8852021 | 0.74 | TSHR (0.44) | TSHRARALDH1A1CYP1A2 | |
| SCHEMBL26094546 | 0.74 | TSHR (0.40) | TSHRARALDH1A1UPP1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702045-B1 | NOVEL PROCESS FOR THE PREPARATION OF ETRAVIRINE | MYLAN LABORATORIES LTD (IN) | 2017-10-18 | — | — | EP | disclosed |
| EP-2342186-B1 | PROCESS FOR SYNTHESIS OF ETRAVIRINE | EMCURE PHARMACEUTICALS LTD (IN) | 2014-09-17 | — | — | EP | disclosed |
| EP-2702045-A1 | NOVEL PROCESS FOR THE PREPARATION OF ETRAVIRINE | Mylan Laboratories, Limited (IN) | 2014-03-05 | — | — | EP | disclosed |
| US-8653266-B2 | Process for the production of etravirine | MYLAN LABORATORIES LIMITED (IN) | 2014-02-18 | — | — | US | disclosed |
| US-20130116433-A1 | PROCESS FOR THE PRODUCTION OF ETRAVIRINE | MYLAN LABORATORIES LIMITED (IN) | 2013-05-09 | — | — | US | disclosed |
| WO-2012147104-A1 | NOVEL PROCESS FOR THE PREPARATION OF ETRAVIRINE | MYLAN LABORATORIES LTD (IN) | 2012-11-01 | — | — | WO | disclosed |
| US-20110196156-A1 | PROCESS FOR SYNTHESIS OF DIARYLPYRIMIDINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | GURJAR MUKUND KESHAV | 2011-08-11 | — | — | US | disclosed |
| EP-2342186-A2 | PROCESS FOR SYNTHESIS OF DIARYLPYRIMIDINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | Emcure Pharmaceuticals Limited (IN) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010150279-A2 | PROCESS FOR SYNTHESIS OF DIARYLPYRIMIDINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | EMCURE PHARMACEUTICALS LIMITED (IN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116433-A1 | PROCESS FOR THE PRODUCTION OF ETRAVIRINE | MCM4, EIF2AK2, EIF5B | TSHR 3941/4885AR 3397/4885ALDH1A1 1656/4885 |
| US-20110196156-A1 | PROCESS FOR SYNTHESIS OF DIARYLPYRIMIDINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | TYMP, DPYD, POLR2H | TSHR 3752/4885AR 3503/4885ALDH1A1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.